Drug Trial Radar · NCT06104566
Global Trial in APG2575 for Patients With CLL/SLL
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Dec 20, 2023
Primary completion
Dec 31, 2026
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Conditions
- CLL/SLL
Interventions
lisaftoclax +BTK inhibitorDrug
lisaftolax + BTK inhibitor
BTK inhibitorDrug
BTK inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: 12 months
Locations
135 sites in 19 countries. Site status is shown where the registry gives one.
Ascentage Investigative Site
Tuscon, Arizona · Recruiting
Ascentage Investigative Site
Anaheim, California · Recruiting
Ascentage Investigative Site
Jacksonville, Florida · Recruiting
Ascentage Investigative Site
Miami Beach, Florida · Recruiting
Ascentage Investigative Site
Peoria, Illinois · Recruiting
Ascentage Investigative Site
Boston, Massachusetts · Recruiting
Ascentage Investigative Site
Ann Arbor, Michigan · Recruiting
Ascentage Investigative Site
Greenville, North Carolina · Recruiting
Ascentage Investigative Site
Houston, Texas · Recruiting
Ascentage Investigative Site
Kingswood, Texas · Recruiting
Ascentage Investigative Site
Richmond, Virginia · Recruiting
Ascentage Investigative Site
Gosford, Australia · Completed
Ascentage Investigative Site
Perth, Australia · Completed
Ascentage Investigative Site
Westmead, Australia · Completed
Ascentage Investigative Site
Ghent, Belgium · Recruiting
Ascentage Investigative Site
La Louvière, Belgium · Recruiting
Ascentage Investigative Site
Leuven, Belgium · Recruiting
Ascentage Investigative Site
Ottignies, Belgium · Recruiting
Ascentage Investigative Site
Roeselare, Belgium · Recruiting
Ascentage Investigative Site
Sofia, Bulgaria · Recruiting
Ascentage Investigative Site
Sofia, Bulgaria · Recruiting
Ascentage Investigative Site
Sofia, Bulgaria · Recruiting
Ascentage Investigative Site
Sofia, Bulgaria · Recruiting
Ascentage Investigative Site
Halifax, Nova Scotia, Canada · Recruiting
Ascentage Investigative Site
Guangzhou, China · Recruiting
Ascentage Investigative Site
Hefei, Anhui, China · Recruiting
Ascentage Investigative Site
Beijing, Beijing Municipality, China · Recruiting
Ascentage Investigative Site
Fuzhou, Fujian, China · Recruiting
Ascentage Investigative Site
Foshan, Guangdong, China · Recruiting
Ascentage Investigative Site
Guangzhou, Guangdong, China · Recruiting
Ascentage Investigative Site
Nanning, Guangxie, China · Recruiting
Ascentage Investigative Site
Zhengzhou, Henan, China · Recruiting
Ascentage Investigative Site
Wuhan, Hubei, China · Recruiting
Ascentage Investigative Site
Chenzhou, Hunan, China · Recruiting
Ascentage Investigative Site
Nanjing, Jiangsu, China · Recruiting
Ascentage Investigative Site
Suzhou, Jiangsu, China · Recruiting
Ascentage Investigative Site
Wuxi, Jiangsu, China · Recruiting
Ascentage Investigative Site
Nanchang, Jiangxi, China · Recruiting
Ascentage Investigative Site
Xi'an, Shaanxi, China · Recruiting
Ascentage Investigative Site
Binzhou, Shandong, China · Recruiting
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.